iBio, Inc. IBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-49.2
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $400,000 | -$18.4M | — | -$15.3M | $14.9M |
| 2024 | $225,000 | -$24.9M | — | -$18.8M | $21.3M |
| 2023 | $0 | -$65.0M | — | -$36.2M | $15.4M |
| 2022 | $1.9M | -$50.3M | $2.2M | -$44.8M | $63.5M |
| 2021 | $2.4M | -$23.2M | $909,000 | -$35.0M | $108.6M |
| 2020 | $1.6M | -$16.4M | $935,000 | -$14.4M | $56.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Banjak Marc | Chief Legal Officer | 2026-03-26 | Buy | 12,500 | $1.64 |
| Banjak Marc | Chief Legal Officer | 2026-03-26 | Buy | 1,434 | $1.76 |
| Duran Felipe | Chief Financial Officer | 2026-03-19 | Buy | 24,835 | $2.02 |
| Brenner Martin | See Remarks | 2026-03-19 | Buy | 12,336 | $2.02 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -49.2 (distress)
- Working capital / assets 0.156
- Retained earnings / assets -14.329
- EBIT / assets -0.802
- Equity / liabilities 1.792
Source: SEC EDGAR filings · CIK 0001420720 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.